Swiss National Bank Cyma Bay Therapeutics, Inc. Transaction History

Swiss National Bank

  • $150 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024
SELL
$12.63 - $24.47 $329,643 - $638,667
-26,100 Reduced 14.38%
155,400 $3.67 Million
Q3 2023

Nov 08, 2023
BUY
$10.86 - $17.62 $245,436 - $398,212
22,600 Added 14.22%
181,500 $2.71 Million
Q2 2023

Aug 09, 2023
SELL
$7.47 - $10.95 $177,786 - $260,609
-23,800 Reduced 13.03%
158,900 $1.74 Million
Q1 2023

May 10, 2023
BUY
$5.88 - $9.59 $1.07 Million - $1.75 Million
182,700 New
182,700 $1.59 Million
Q2 2021

Aug 06, 2021
SELL
$3.94 - $4.92 $429,460 - $536,280
-109,000 Closed
0 $0
Q4 2020

Feb 05, 2021
BUY
$5.73 - $9.03 $624,570 - $984,269
109,000 New
109,000 $626,000
Q2 2020

Aug 05, 2020
SELL
$1.41 - $4.25 $166,944 - $503,200
-118,400 Closed
0 $0
Q4 2019

Feb 06, 2020
BUY
$1.33 - $5.93 $3,325 - $14,825
2,500 Added 2.16%
118,400 $232,000
Q3 2019

Nov 12, 2019
BUY
$5.12 - $7.21 $15,360 - $21,630
3,000 Added 2.66%
115,900 $593,000
Q2 2019

Aug 02, 2019
BUY
$6.05 - $13.66 $13,915 - $31,418
2,300 Added 2.08%
112,900 $808,000
Q1 2019

May 10, 2019
BUY
$8.16 - $13.42 $93,024 - $152,988
11,400 Added 11.49%
110,600 $1.47 Million
Q4 2018

Feb 13, 2019
BUY
$6.54 - $11.74 $16,350 - $29,350
2,500 Added 2.59%
99,200 $781,000
Q2 2018

Aug 09, 2018
BUY
$10.66 - $14.38 $1.03 Million - $1.39 Million
96,700 New
96,700 $1.3 Million

Others Institutions Holding CBAY

# of Institutions
6
Shares Held
1.82M
Call Options Held
0
Put Options Held
0
View Full List

About CymaBay Therapeutics, Inc.

CBAY Quotes by TradingView
  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email